A phase1 basket trial of GTB-5550 for the treatment in multiple solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GTB 5550 (Primary)
Indications Advanced breast cancer; Gastrointestinal cancer; Head and neck cancer; Liver cancer; Lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
Focus Adverse reactions

14 Aug 2024 According to a GT Biopharma media release, IND submission for treatment of B7H3 positive solid tumors expected in 1H 2025. Phase 1 dose escalation basket trial initiation expected in 2025 evaluating six solid tumor types, including prostate, breast, head and neck, ovarian, lung, and GI.
27 Jun 2024 According to a GT Biopharma media release, company is looking forward to submitting the IND in the first quarter of 2025.
15 May 2024 According to a GT Biopharma media release, trial is expected to start in early 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com